Vitamin D Inadequacy on Postprandial Glucose in Type 2 Diabetes Mellitus

Impacts of Vitamin D Inadequacy on Postprandial Glucose Excursion in Patients With Type 2 Diabetes

Vitamin D deficiency is associated with an unfavorable metabolic profile in several observational studies. However, the influences of vitamin D concentrations on postprandial glucose in type 2 diabetes (DM) are less studied. The purposes of the study are to study the effects of vitamin D inadequacy on postprandial glucose excursion and metabolic responses in patients with type 2 DM. This is a cross-sectional study. About 150-180 patients will be screened for serum levels of 25(OH)D. A total of 45 eligible patients will be grouped into three groups by different vitamin D status: vitamin D deficiency, vitamin D insufficiency, and the controls. The patients will receive a mixed meal test for postprandial glucose excursion and metabolic responses. The investigators will use statistical methods to assess the differences in post-challenge glucose and metabolic response among the three groups of patients. The investigators hope the study can explore the relationship between vitamin D and glucose excursion in patients with type 2 DM.

Study Overview

• Status: Unknown
• Conditions: Type 2 Diabetes

Detailed Description

Vitamin D deficiency is associated with an unfavorable metabolic profile in several observational studies. However, the influences of vitamin D concentrations on postprandial glucose in type 2 diabetes (DM) are less studied. The purposes of the study are to study the effects of vitamin D inadequacy on postprandial glucose excursion and metabolic responses in patients with type 2 DM. This is a cross-sectional study. About 150-180 patients will be screened for serum levels of 25(OH)D. A total of 45 eligible patients will be grouped into three groups by different vitamin D status: vitamin D deficiency, vitamin D insufficiency, and the controls. The patients will receive a mixed meal test for postprandial glucose excursion and metabolic responses. Analysis of variance (ANOVA) will be applied to compare the differences in clinical characteristics among the three groups. Univariate analyses of general linear models will be used to compare the differences in meal-derived metabolic indexes among the three groups, showing effects of confounding variables including age, sex, obesity, and DM-related clinical parameters. Repeated-measures ANOVA will be used to assess the differences in post-challenge glucose and metabolic response in the meal test, with or without adjustments of the above covariates. Pearson and partial correlation procedures will be used to test the correlations of 25(OH)D with clinical parameters including lipid profile, HbA1c, and meal-derived metabolic indexes. Multiple linear regression models will be used in an attempt to compare the degree to which 25(OH)D concentrations is associated with the meal-derived metabolic indexes in these patients. The investigators hope the study can explore the relationship between vitamin D and glucose excursion in patients with type 2 DM.

• Study Type: Observational
• Enrollment (Anticipated): 45

Contacts and Locations

• Study Contact: Name: Chii-Min Hwu, MD; Phone Number: 886228757516; Email: chhwu@vghtpe.gov.tw

Study Locations

• Taiwan
  • Taipei, Taiwan, 112
    • Recruiting
    • Taipei Veterans General Hospital
    • Principal Investigator: Chii-Min Hwu, MD
    • Contact: Chii-Min Hwu, MD; Phone Number: 8862287516; Email: chhwu@vghtpe.gov.tw

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

In the present study, we propose to screen patients with type 2 DM for vatamin D inadequacy. Those with different vitamin D status will be invited to participate in a mixed meal test.

Description

Inclusion Criteria:

• Ambulatory type 2 diabetes patients.
• Men or women.
• Aged 20 ~ 75 years old.
• Stable oral anti-diabetes therapy for at least 8 weeks.
• Willing to participate in the study by signing an informed consent.
• Willing to undergo a screening visit including medical history taking and fasting blood sampling.
• Willing to undergo a standardized mixed meal test at a separate visit.

Exclusion Criteria:

• Patients of type 2 diabetes with the following: History of HHNK; Fasting glucose higher than 250 mg/dL; Treated with insulin, alpha-glucosidase inhibitor, incretin mimetics, DPP-IV inhibitors or rapid-acting insulin secretagogus (the meglitinides) in the past 8 weeks;
• HbA1c > 8.5 %.
• History or evidence of parathyroid or calcium-related diseases.
• History or evidence of endocrine diseases including hyperthyroidism, hypothyroidism, adrenal disease and pituitary disease.
• History of major renal, liver, heart, blood and neurological disease, judged by the investigation physicians.
• History or evidence of alcoholism or drug abuse.
• History of surgical operation of upper gastrointestinal tract and liver. Women who are pregnant.
• History of malignancy within the last 5 years
• History of mental incapacity or language barriers that may preclude adequate understanding or cooperation in the study.
• Under systemic glucocorticoid therapy in the past 8 weeks
• Under supplementation of vitamin D, of any kind, in the past 4 weeks
• Under hormonal replacement therapy in the past 8 weeks
• Under treatments for osteoporosis including calcitonin and biphosphate in the past 8 weeks.
• History or evidence of difficult venous access
• Subjects with the following laboratory values: hemoglobin < 9 g/dL, WBC < 3000/mL, platelet < 100,000/mL, serum Cr > 2.0 mg/dL, ALT > 3x ULN, total bilirubin > 2x ULN.
• Current or concomitant illness that would interfere with the subject's ability to perform the study or that would confound the study results, judged by the investigation physicians.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
Vitamin D deficiency; patients with serum vitamin D levels of the lower tertile
Vitamin D inadequacy; patients with serum vitamin D levels of the middle tertile
Reference group; patients with serum vitamin D levels of the upper tertile

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
incremental areas under the curves of plasma glucose after meal challenge	Within 20 days of the screening visit, the eligible participants will receive a 3-h mixed meal test for postprandial glucose excursion.	20 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
insulin sensitivity and β-cell function indexes from the meal test	Within 20 days of the screening visit, the eligible participants will receive a 3-h mixed meal test for postprandial glucose excursion.	20 days
Meal-related glycemic excursion indexes (∆G, ∆T, BR)from the meal test	Within 20 days of the screening visit, the eligible participants will receive a 3-h mixed meal test for postprandial glucose excursion.	20 days

Collaborators and Investigators

• Sponsor: Taipei Veterans General Hospital, Taiwan
• Investigators: Principal Investigator: Chii-Min Hwu, MD, Taipei Veterans General Hospital, Taiwan

Study record dates

Study Major Dates

• Study Start: August 1, 2011
• Primary Completion (Anticipated): July 1, 2012
• Study Completion (Anticipated): December 1, 2012

Study Registration Dates

• First Submitted: December 6, 2011
• First Submitted That Met QC Criteria: December 7, 2011
• First Posted (Estimate): December 8, 2011

Study Record Updates

• Last Update Posted (Estimate): December 14, 2011
• Last Update Submitted That Met QC Criteria: December 12, 2011
• Last Verified: December 1, 2011

More Information

Terms related to this study

• Keywords: Vitamin D; Type 2 Diabetes; Postprandial Glucose
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: V100C-144-Protocol-1